Vaccine Decision Making ecosystem in Southern Africa

Annual African Vaccinology Conference 2025

Dr A N Masu
Email:
adelaide.masu@uct.ac.za

07 November 2025













Co-investigators

- Benjamin Kagina
- Edina Amponsah- Dacosta
- Rudzani Muloiwa
- Alana Keyser





Background

Vaccine decision	Vaccine prioritisation
making	Competing health interests
Stakeholders	Multiple
Stakenotaers	Internal
	External
NITAGs	Key
	Evidence to Recommendations
Surveillance VPD	Data Availability
	Data driven decision making





Aim

• The aim of this study is to describe vaccine-decision making ecosystem in Namibia, Botswana, Eswatini and South Africa.





Methods


Interviews

- Study recruitment: stakeholders
 - NITAG members
 - WHO/ UNICEF members
 - o MOH representative: EPI manager
 - o MOF representative
- Interview:
 - o Semi-structured- Interview guide
 - One hour long
 - o MS teams
 - Recorded and transcription





Results



- 3 countries (Eswatini no participation)
 - Botswana
 - Namibia
 - South Africa
- Respondents
 - -8
 - NITAG/ WHO/ EPI mangers
 - No MOF representative





Priorities

Priority	Details
Competing interests	 Health: COVID 19 pandemic Other Natural disaster: floods and drought Conflict and humanitarian crisis
Vaccine preventable diseases (VPD)	 VPDs targeted in EPI Specific e.g. Polio: neighbouring country outbreaks Measles: frequent outbreaks Rotavirus outbreaks





Stakeholders

Stakeholder	Details
NITAG	 Evidence-based recommendations Adopted by government for countries with recent recommendation Support for this role Secretariat Resources
Government	 Ministry of health: Motivation for funding; Final decision maker; Implementation (EPI) Ministry of finance: Find budget Other ministries: Intersectoral collaboration: Ministry of education, Family sector






Stakeholders

Stakeholder	Details
Assistant partners (WHO & UNICEF)	 Logistical support: Provision of experts Part of technical working groups SAGE recommendations
GAVI	 GAVI, the alliance Support LIC, now some MIC (Eswatini) Self financing
Pharmaceutical company	 Registration of vaccine with Drug and council Information about vaccine product







Factors

Vaccine safety and effectiveness:

- Availability of vaccines in country
- Vaccine efficacy
 - Important
 - If similar efficacy, price factors
- Cost

Recommendations:

- NITAG: Adoption
- WHO/ SAGE: Trigger

Target population

- Mother/ children
- HIV (high burden some countries)

Political landscape:

- High political will
- Change of leadership affects decision making
- Lack of background in immunisation

Health system impact

- Cost/ benefit decrease hospitalisation, antibiotic use, death
- Increase workload staff





Facilitators

Facilitator	Details
Supportive legislation	 Framework for right to health Enshrined in the constitution
Strong local data	 In country for unique contexts e.g. HIV Burden Local research- Universities
Strong EPI program	Strong managementUniversity role in policy
Local manufacturing	Increase vaccine availabilityAfrica huge marketLack of investment





Facilitators

Facilitator	Details
Communication and co-ordination	 Immunisation stakeholders Inclusive global and local Ongoing communication: recommendations/ vaccines/ outside of vaccine introduction
Community	 Role of community Rights Centre of decision-making process
Vaccine access	 Affordability and accessibility of vaccines: Equity Rights of community
Advocacy	Health care workersOther partners e.g. assistance partners





Barriers

Barrier	Details
Vaccine registration	Restricted choiceDetermines vaccine availability
Vaccine hesitancy	Access to technologyMisinformation
Human resources	Lack of appropriate human resourcesLack of training
Health systems	Lack of reach of populationFragile health systems
Finances	Self financingCost of vaccineFailure to adopt recommendations





Surveillance

Surveillance	Details
Local data	Present some conditionsUse of neighbouring countries
Several components	 Outbreak/ environmental/ sentinel/ case based Shared use of resources e.g. laboratory networks
Funding	Government fundedCatalyst funds for specific programs





Discussion

Priorities:

Factors beyond control

Competing interests

Stakeholders

Government ministries

Role of NITAGs

Pharmaceutical industry

WHO

Higher Education Institutes

Finances

Sustainability

Priorities in LMIC

Vaccine Equity





Discussion

Local manufacturing

Factors beyond control

Vaccine Hesitano

Widespread

Hesitancy Strategies

Surveillance

Fragmented

Funding









Thank You for Attending

mish-africa.org

mish@uct.ac.za